BioNTech SE (NASDAQ:BNTX) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ET
Company Participants
Victoria Meissner - VP, Strategy & IR
Ugur Sahin - Co-Founder & CFO
Ozlem Tureci - Chief Medical Officer & Co-Founder
Jens Holstein - CFO
Ryan Richardson - Chief Strategy Officer
Conference Call Participants
Daina Graybosch - Leerink Partners
Tazeen Ahmad - Bank of America
Chris Shibutani - Goldman Sachs
Yaron Werber - TD Cowen
Jessica Fye - JPMorgan
Bill Maughan - Canaccord Genuity
Simon Baker - Redburn Atlantic
Ellie Merle - UBS
Operator
Welcome to the BioNTech Third Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead.
Victoria Meissner
Thank you. Good morning and afternoon. Thank you for joining us today for BioNTech's Third Quarter 2023 Earnings Call. As a reminder, the slides that accompany this call and the press release issued this morning can be found in the investor section of our website.
On the next slide, you can see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings made with the U.S. Securities and Exchange Commission. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements.
On Slide 3, you can find the agenda for today's call. Today I'm joined by the following members of BioNTech's management team. Our CEO and Co-Founder, Ugur Sahin; Ozlem Tureci, our Chief Medical Officer and Co-Founder; Jens Holstein, our Chief Financial Officer; and Ryan Richardson, our Chief Strategy Officer.
I would like to turn the call over to Ugur Sahin.
Ugur Sahin
Thank you, Victoria. A warm welcome to all those joining us today. I will summarize our third quarter highlights before turning to my colleagues, who will provide further details.
Slide 5. Let me start by providing an overview of our strategic priorities and latest achievements. This quarter we continue to build on our global COVID-19 vaccine leadership with first to market Omicron XBB.1.5-adapted vaccine launches across multiple regions worldwide. I thank our team and collaborators for their tireless efforts to make this accomplishment possible, again, in such a short period of time. Our COVID-19 influenza combination program, run in partnership with Pfizer, leveraging our proprietary mRNA technology has also reported positive top-line results. The Phase 1/2 study evaluating the safety, tolerability, and immunogenicity of co-administered mRNA-based vaccine candidates for COVID-19 and influenza among healthy adults 18 to 64 years of age when compared to a licensed influenza vaccine, demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains, as well as a safety profile consistent with the safety profile of the companies’ COVID-19 vaccine. A pivotal Phase 3 study will be initiated in the coming months.